

ACC 2024 Rapid Reaction: Part II References

Special Guest: Snehal Bhatt, PharmD, BCPS, FASHP, AACC

Featured Articles

Butler J, Jones WS, Udell JA, et al. Empagliflozin after Acute Myocardial Infarction. *N Engl J Med*. 2024 Apr 25;390(16):1455-1466. <https://pubmed.ncbi.nlm.nih.gov/38587237/>

ULTIMATE-DAPT investigators. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. *Lancet*. 2024 Apr 5:S0140-6736(24)00473-2. doi: 10.1016/S0140-6736(24)00473-2. Epub ahead of print. <https://pubmed.ncbi.nlm.nih.gov/38599220/>

Guidelines/Statements

ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2018 Jan 7;39(2):119-177. <https://pubmed.ncbi.nlm.nih.gov/28886621/>

CF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013 Jan 29;127(4):529-55. <https://pubmed.ncbi.nlm.nih.gov/23247303/>

ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2021 Apr 7;42(14):1289-1367. <https://pubmed.ncbi.nlm.nih.gov/32860058/>

Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014 Dec 23;64(24):e139-e228. <https://pubmed.ncbi.nlm.nih.gov/25260718/>

Articles Referenced in the Episode

James S, Erlinge D, Storey RF, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. *NEJM Evid*. 2024 Feb;3(2):EVIDoa2300286.

<https://pubmed.ncbi.nlm.nih.gov/38320489/>

PARADISE-MI Investigators and Committees. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. *N Engl J Med*. 2021 Nov 11;385(20):1845-1855.

<https://pubmed.ncbi.nlm.nih.gov/34758252/>

Harrington J, Udell JA, Jones WS, et al. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. *Am Heart J*. 2022 Nov;253:86-98.

<https://pubmed.ncbi.nlm.nih.gov/35595091/>

Hernandez AF, Udell JA, Jones WS, et al. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial. *Circulation*. 2024 Apr 6. doi: 10.1161/CIRCULATIONAHA.124.069217. Epub ahead of print.

<https://pubmed.ncbi.nlm.nih.gov/38581389/>

Udell JA, Petrie MC, Jones WS, et al. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction. *J Am Coll Cardiol*. 2024 Apr 6:S0735-1097(24)06757-3. <https://pubmed.ncbi.nlm.nih.gov/38588929/>

Ge Z, Gao XF, Kan J, et al. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial. *Am Heart J*. 2021 Jun;236:49-58. <https://pubmed.ncbi.nlm.nih.gov/33621541/>

IVUS-ACS Investigators. Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial. *Lancet*. 2024 Apr 5:S0140-6736(24)00282-4. doi: 10.1016/S0140-6736(24)00282-4. Epub ahead of print. <https://pubmed.ncbi.nlm.nih.gov/38604212/>